MTA3はMi-2/NuRD複合体のサブユニットで,乳がんにおける侵襲的な成長経路を調節する

Naoyuki Fujita¹, David L Jaye, Masahiro Kajita

¹Emory University School of Medicine, Department of Pathology, Whitehead Biomedical Research Building, Room 142, 615 Michael Street, Atlanta, GA 30322, USA.

Cell

|April 23, 2003

まとめ

エストロゲン受容体とMTA3は乳がんの成長と分化を調節する. その欠如により,スナイルが増加し,E-cadherinを減少させることで侵襲的な成長を促します.

科学分野:

分子生物学は分子生物学である.
がん生物学がん生物学
細胞生物学細胞生物学

背景:

エストロゲン受容体 (ER) は乳腺の発達に不可欠であり,乳がんの主要な標的である.
ERは遺伝子発現を通じて細胞増殖と分化に影響を与えます.
ERのダウンストリーム効果因子を理解することは,乳がん治療において極めて重要です.

研究の目的:

乳腺上皮細胞の新種のエストロゲン依存性レギュレータを特定する.
ER媒介経路におけるMTA3の役割を明らかにする.
ERステータスと乳がんの侵襲性との間にメカニズム的なリンクを確立する.

主な方法:

Mi-2/NuRDトランスクリプションコアプレッサー複合体におけるヒトMTA3の役割を調査した.
エストロゲン受容体とMTA3欠乏がスナイルの発現に与える影響を分析した.
異常なスナイル発現がE-カデリンと上皮構造に与える影響を評価した.

主要な成果:

MTA3は,乳腺細胞におけるMi-2/NuRD複合体のエストロゲン依存成分として特定されました.
ERまたはMTA3の欠如は,スナイル・レプレッサーの異常な発現につながる.
アバラントスナイル発現は,E-カデリンの減少につながり,侵入的成長を促します.

結論:

MTA3は,乳房細胞の成長と分化を制御するエストロゲン依存の経路の重要な媒介者です.
エストロゲン受容体とMTA3経路の障害は,侵襲性乳がんのフェノタイプと関連しています.
この研究は,ER状態と乳がんにおける侵襲的な成長の間のメカニズム的な関連性を確立しています.

さらに関連する動画

12:19

Three-Dimensional (3D) Tumor Spheroid Invasion Assay

Published on: May 1, 2015

08:12

The Use of Mouse Mammary Tumor Cells in an In Vitro Invasion Assay as a Measure of Oncogenic Cell Behavior

Published on: June 12, 2019

関連する概念動画

02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...

02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...